News | February 23, 2023
Research underscores Beyfortus’ potential to prevent RSV disease in infants
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Subscribe To Our Newsletter & Stay Updated
